Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsBlends & Stacks1 : 1 Ratio Blend / StackFemale-friendly

CagriSema (Semaglutide + Cagrilintide)

Also known as: CagriSema 1:1 Blend, Semaglutide + Cagrilintide Stack, Dual GLP-1 + Amylin Agonist

Dose Range
0.25 mgResearch range
0Typical research window: 0.25 mg0.5 mg

Studied in published research — not a medical recommendation. Primary protocol (REDEFINE-1 1:1 Weekly Titration Protocol): 0.25 mg / 0.25 mg starting dose -> titrate every 4 weeks up to 2.4 mg / 2.4 mg max, Once weekly.

Protocol at a Glance
How Often
Once weekly

Once weekly

A Typical Run
68 weeks

Research-reported range; the linked study used a different dose or units. Always start at 0.25mg/0.25mg; escalating Cagrilintide too fast causes pronounced early satiety and fatigue

How It's Taken
Vial

Subcutaneous injection

Evidence
Established

Human clinical trials or FDA-approved formulation exists

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 0.25 mg10 units

All U-100: 100 units = 1 mL. 20 doses in the vial at the low end.

Track the doses you run

Save CagriSema (Semaglutide + Cagrilintide) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Phase 2/3 Clinical TrialsTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Dual GLP-1 + Amylin / Calcitonin Receptor Co-Agonist
Administration Route
Under-the-skin injection (Subcutaneous injection)
2026 FDA & 503A Status
Active Phase 2/3 human clinical trials in 2026; not yet FDA-approved for commercial prescription or 503A bulk pharmacy compounding. Sold strictly as an analytical laboratory reference standard.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a GLP-1 Agonist?

A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.

Bottom Line Up Front

CagriSema combines Semaglutide (GLP-1 agonist) with Cagrilintide (long-acting amylin/calcitonin dual receptor agonist). Clinical trials and pre-mixed vials use a 1:1 ratio (2.5mg/2.5mg or 5mg/5mg titrated from 0.25/0.25 mg weekly), while many independent researchers prefer separate vials (3:1 to 5:1 ratio) to titrate Cagrilintide more slowly (0.25–0.5 mg/week).

Best evidence for

Published preclinical & translational clinical protocols

Weakest evidence for

Large multi-year outcomes in healthy non-clinical cohorts

Pharma equivalent

None

Studies on file

3 (0 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. CagriSema (Semaglutide + Cagrilintide) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

CagriSema is a next-generation metabolic combination pairing Semaglutide (GLP-1R agonist) with Cagrilintide (a lipidated long-acting DACRA targeting amylin AMY1–3 and calcitonin receptors in the area postrema). Because GLP-1 and amylin act on distinct, non-overlapping satiety centers in the hypothalamus and brainstem, combining them overcomes GLP-1 monotherapy plateaus and produced 22.7% mean weight reduction in the 68-week Phase 3 REDEFINE-1 trial.

Mechanisms of Action

  • Semaglutide activates hypothalamic and pancreatic GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress appetite
  • Cagrilintide activates amylin (AMY1R/AMY3R) and calcitonin receptors in the area postrema and nucleus tractus solitarius
  • Dual-pathway synergy slows gastric emptying, blunts postprandial glucagon, and restores leptin sensitivity during caloric deficit

Common Ratios, Vial Formats & Dosing Breakdown

Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.

Open in Blend Calculator
1 : 1 Ratio

1:1 Fixed Clinical Ratio (REDEFINE Trial / Pre-Mixed Vial)

Calculate draw units →
Vial / Stack Breakdown

2.5mg Semaglutide / 2.5mg Cagrilintide (5mg total) or 5mg / 5mg (10mg total)

Typical Dosing & Syringe Draw

Start 0.25mg + 0.25mg once weekly; titrate every 4 weeks (0.5/0.5 -> 1.0/1.0 -> 1.7/1.7 -> 2.4/2.4 mg)

Why this ratio: Matches Novo Nordisk's fixed-dose co-formulation. With a 5mg/5mg vial + 2mL BAC water, 10 units = 250 mcg of each.

3 : 1 to 5 : 1 Ratio (Separate Vials)

Separate-Vial Asymmetric Layering (Low-Nausea Protocol)

Vial / Stack Breakdown

5mg Semaglutide vial + 5mg Cagrilintide vial (separate)

Typical Dosing & Syringe Draw

1.0–2.0 mg Semaglutide weekly + 0.25–0.5 mg Cagrilintide staggered 3.5 days later

Why this ratio: Preferred by many users because Cagrilintide provides strong satiety at just 0.25–0.5 mg/week without requiring a full 1:1 match.

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
REDEFINE-1 1:1 Weekly Titration Protocol
reported protocol
0.25 mg / 0.25 mg starting dose -> titrate every 4 weeks up to 2.4 mg / 2.4 mg maxOnce weekly68 weeksSubcutaneous injectionclinical trial
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (CagriSema (Semaglutide + Cagrilintide))

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Never mix Semaglutide and Cagrilintide in the same syringe for long-term storage unless buffered appropriately (commercial CagriSema uses a dual-chamber pen due to pH differences)
  • •Monitor for GI adverse events (nausea, delayed gastric emptying); contraindicated in MTC/MEN2 history
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get CagriSema (Semaglutide + Cagrilintide), baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.